市場調査レポート
商品コード
1063908

CAR-T細胞療法の世界市場、製品タイプ別、腫瘍タイプ別、適応別、治療タイプ別、標的抗原別、エンドユーザー別、地域別、競争、予測、機会、2017年~2027年

Global CAR-T Cell Therapy Market, By Product Type, By Tumor Type, By Indication, By Treatment Type, By Targeted Antigen, By End User, By Region, Competition, Forecast and Opportunities, 2017-2027

出版日: | 発行: TechSci Research | ページ情報: 英文 283 Pages | 納期: 2~3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.52円

こちらのレポートには、数時間(ご購入金額の10%)分のアナリストへの質問/追加調査サービスが含まれております。

CAR-T細胞療法の世界市場、製品タイプ別、腫瘍タイプ別、適応別、治療タイプ別、標的抗原別、エンドユーザー別、地域別、競争、予測、機会、2017年~2027年
出版日: 2022年03月01日
発行: TechSci Research
ページ情報: 英文 283 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のCAR-T細胞療法の市場規模は、2021年に17億900万米ドルとなりました。

同市場は、予測期間である2023年~2027年に64.66%のCAGRで拡大し、2027年には331億5,330万米ドルに達すると予測されています。

世界的に癌の発生率が上昇しており、癌による死亡率が増加していることが、今後5年間の世界のCAR-T細胞療法市場の成長を牽引しています。政府の制度や税制優遇措置、治療のための保険制度、経済的支援が得られない患者に安価な治療を提供するために活動するNGOの増加が、同市場の成長を促進するとみられています。

当レポートでは、世界のCAR-T細胞療法市場について調査し、市場の概要とともに、製品タイプ別、腫瘍タイプ別、適応別、治療タイプ別、標的抗原別、エンドユーザー別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 製品の概要

第2章 調査手法

第3章 COVID-19が世界のCAR-T細胞療法市場に与える影響

第4章 エグゼクティブサマリー

第5章 顧客の声

第6章 世界のCAR-T細胞療法市場の見通し

  • 市場規模と予測
  • 市場シェアと予測
    • 製品タイプ別
    • 腫瘍タイプ別
    • 適応別
    • 治療タイプ別
    • 標的抗原別
    • エンドユーザー別
    • 地域別
    • 企業別
  • 製品市場マップ

第7章 北米のCAR-T細胞療法市場の見通し

  • 市場規模と予測
  • 市場シェアと予測
  • 北米:国別分析

第8章 欧州のCAR-T細胞療法市場の見通し

  • 市場規模と予測
  • 市場シェアと予測
  • 欧州:国別分析

第9章 アジア太平洋のCAR-T細胞療法市場の見通し

  • 市場規模と予測
  • 市場シェアと予測
  • アジア太平洋:国別分析

第10章 南米のCAR-T細胞療法市場の見通し

  • 市場規模と予測
  • 市場シェアと予測
  • 南米:国別分析

第11章 中東・アフリカのCAR-T細胞療法市場の見通し

  • 市場規模と予測
  • 市場シェアと予測
  • 中東・アフリカ:国別分析

第12章 市場力学

  • 促進要因
  • 課題

第13章 市場の動向と発展

第14章 競合情勢

  • 競合の見通し
  • 企業プロファイル
    • Gilead Sciences, Inc
    • Novartis International AG
    • Bristol Myers Squibb Co.
    • AbbVie Inc.
    • Cellectis SA
    • Amgen Inc
    • Pfizer Inc.
    • Merck & Co. Inc.
    • Intellia Therapeutics Inc.
    • Poseida Therapeutics Inc
    • Johnson & Johnson
    • Allogene Therapeutics Inc
    • Autolus Therapeutics PLC
    • Humanigen, Inc.
    • Sangamo Therapeutics, Inc.

第15章 戦略的推奨事項

図表

List of Figures

  • Figure 1: Global CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F
  • Figure 2: Global CAR-T Cell Therapy Market Share, By Product Type, By Value, 2017-2027F
  • Figure 3: Global CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F
  • Figure 4: Global CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F
  • Figure 5: Global CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F
  • Figure 6: Global CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F
  • Figure 7: Global CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F
  • Figure 8: Global CAR-T Cell Therapy Market Share, By Region, By Value, 2017-2027F
  • Figure 9: Global CAR-T Cell Therapy Market Share, By Company, By Value, 2021
  • Figure 10: Global CAR-T Cell Therapy Market Map, By Product Type, Market Size (USD Million) & Growth Rate (%), 2021
  • Figure 11: Global CAR-T Cell Therapy Market Map, By Indication, Market Size (USD Million) & Growth Rate (%), 2021
  • Figure 12: Global CAR-T Cell Therapy Market Map, By Region, Market Size (USD Million) & Growth Rate (%), 2021
  • Figure 13: North America CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F
  • Figure 14: North America CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F
  • Figure 15: North America CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F
  • Figure 16: North America CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F
  • Figure 17: North America CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F
  • Figure 18: North America CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F
  • Figure 19: North America CAR-T Cell Therapy Market Share, By Country, By Value, 2017-2027F
  • Figure 20: United States CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F
  • Figure 21: United States CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F
  • Figure 22: United States CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F
  • Figure 23: United States CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F
  • Figure 24: United States CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F
  • Figure 25: United States CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F
  • Figure 26: Canada CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F
  • Figure 27: Canada CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F
  • Figure 28: Canada CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F
  • Figure 29: Canada CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F
  • Figure 30: Canada CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F
  • Figure 31: Canada CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F
  • Figure 32: Mexico CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F
  • Figure 33: Mexico CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F
  • Figure 34: Mexico CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F
  • Figure 35: Mexico CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F
  • Figure 36: Mexico CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F
  • Figure 37: Mexico CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F
  • Figure 38: Europe CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F
  • Figure 39: Europe CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F
  • Figure 40: Europe CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F
  • Figure 41: Europe CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F
  • Figure 42: Europe CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F
  • Figure 43: Europe CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F
  • Figure 44: Europe CAR-T Cell Therapy Market Share, By Country, By Value, 2017-2027F
  • Figure 45: Germany CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F
  • Figure 46: Germany CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F
  • Figure 47: Germany CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F
  • Figure 48: Germany CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F
  • Figure 49: Germany CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F
  • Figure 50: Germany CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F
  • Figure 51: France CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F
  • Figure 52: France CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F
  • Figure 53: France CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F
  • Figure 54: France CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F
  • Figure 55: France CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F
  • Figure 56: France CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F
  • Figure 57: Switzerland CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F
  • Figure 58: Switzerland CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F
  • Figure 59: Switzerland CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F
  • Figure 60: Switzerland CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F
  • Figure 61: Switzerland CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F
  • Figure 62: Switzerland CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F
  • Figure 63: United Kingdom CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F
  • Figure 64: United Kingdom CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F
  • Figure 65: United Kingdom CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F
  • Figure 66: United Kingdom CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F
  • Figure 67: United Kingdom CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F
  • Figure 68: United Kingdom CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F
  • Figure 69: Italy CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F
  • Figure 70: Italy CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F
  • Figure 71: Italy CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F
  • Figure 72: Italy CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F
  • Figure 73: Italy CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F
  • Figure 74: Italy CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F
  • Figure 75: Spain CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F
  • Figure 76: Spain CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F
  • Figure 77: Spain CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F
  • Figure 78: Spain CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F
  • Figure 79: Spain CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F
  • Figure 80: Spain CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F
  • Figure 81: Asia-Pacific CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F
  • Figure 82: Asia-Pacific CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F
  • Figure 83: Asia-Pacific CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F
  • Figure 84: Asia-Pacific CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F
  • Figure 85: Asia-Pacific CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F
  • Figure 86: Asia-Pacific CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F
  • Figure 87: Asia-Pacific CAR-T Cell Therapy Market Share, By Country, By Value, 2017-2027F
  • Figure 88: China CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F
  • Figure 89: China CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F
  • Figure 90: China CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F
  • Figure 91: China CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F
  • Figure 92: China CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F
  • Figure 93: China CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F
  • Figure 94: Japan CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F
  • Figure 95: Japan CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F
  • Figure 96: Japan CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F
  • Figure 97: Japan CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F
  • Figure 98: Japan CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F
  • Figure 99: Japan CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F
  • Figure 100: India CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F
  • Figure 101: India CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F
  • Figure 102: India CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F
  • Figure 103: India CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F
  • Figure 104: India CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F
  • Figure 105: India CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F
  • Figure 106: Australia CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F
  • Figure 107: Australia CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F
  • Figure 108: Australia CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F
  • Figure 109: Australia CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F
  • Figure 110: Australia CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F
  • Figure 111: Australia CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F
  • Figure 112: South Korea CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F
  • Figure 113: South Korea CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F
  • Figure 114: South Korea CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F
  • Figure 115: South Korea CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F
  • Figure 116: South Korea CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F
  • Figure 117: South Korea CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F
  • Figure 118: South America CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F
  • Figure 119: South America CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F
  • Figure 120: South America CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F
  • Figure 121: South America CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F
  • Figure 122: South America CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F
  • Figure 123: South America CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F
  • Figure 124: South America CAR-T Cell Therapy Market Share, By Country, By Value, 2017-2027F
  • Figure 125: Brazil CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F
  • Figure 126: Brazil CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F
  • Figure 127: Brazil CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F
  • Figure 128: Brazil CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F
  • Figure 129: Brazil CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F
  • Figure 130: Brazil CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F
  • Figure 131: Argentina CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F
  • Figure 132: Argentina CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F
  • Figure 133: Argentina CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F
  • Figure 134: Argentina CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F
  • Figure 135: Argentina CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F
  • Figure 136: Argentina CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F
  • Figure 137: Colombia CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F
  • Figure 138: Colombia CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F
  • Figure 139: Colombia CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F
  • Figure 140: Colombia CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F
  • Figure 141: Colombia CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F
  • Figure 142: Colombia CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F
  • Figure 143: Middle East & Africa CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F
  • Figure 144: Middle East & Africa CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F
  • Figure 145: Middle East & Africa CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F
  • Figure 146: Middle East & Africa CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F
  • Figure 147: Middle East & Africa CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F
  • Figure 148: Middle East & Africa CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F
  • Figure 149: Middle East & Africa CAR-T Cell Therapy Market Share, By Country, By Value, 2017-2027F
  • Figure 150: Israel CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F
  • Figure 151: Israel CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F
  • Figure 152: Israel CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F
  • Figure 153: Israel CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F
  • Figure 154: Israel CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F
  • Figure 155: Israel CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F
  • Figure 156: Saudi Arabia CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F
  • Figure 157: Saudi Arabia CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F
  • Figure 158: Saudi Arabia CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F
  • Figure 159: Saudi Arabia CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F
  • Figure 160: Saudi Arabia CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F
  • Figure 161: Saudi Arabia CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F
  • Figure 162: UAE CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F
  • Figure 163: UAE CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F
  • Figure 164: UAE CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F
  • Figure 165: UAE CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F
  • Figure 166: UAE CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F
  • Figure 167: UAE CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F
  • Figure 168: South Africa CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F
  • Figure 169: South Africa CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F
  • Figure 170: South Africa CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F
  • Figure 171: South Africa CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F
  • Figure 172: South Africa CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F
  • Figure 173: South Africa CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F

List of Tables

  • Table 1: Global Cancer Statistics, 2020
  • Table 2: Total Number of New Cancer Cases and Deaths Reported Globally, By Type, 2020
  • Table 3: Details of FDA Approved CAR-T Cell Therapies (As of February 2022)
  • Table 4: North America Cancer Statistics, 2020
  • Table 5: Total Number of New Cancer Cases and Deaths Reported in North America, By Type, 2020
  • Table 6: Europe Cancer Statistics, 2020
  • Table 7: Total Number of New Cancer Cases and Deaths Reported in Europe, By Type, 2020
  • Table 8: Asia-Pacific Cancer Statistics, 2020
  • Table 9: Total Number of New Cancer Cases and Deaths Reported in Asia Pacific, By Type, 2020
  • Table 10: South America Cancer Statistics, 2020
  • Table 11: Total Number of New Cancer Cases and Deaths Reported in South America, By Type, 2020
  • Table 12: Middle East & Africa Cancer Statistics, 2020
  • Table 13: Total Number of New Cancer Cases and Deaths Reported in Middle East, By Type, 2020
目次
Product Code: 5168

Global CAR-T cell therapy market value in the year 2021 was valued at USD1709 million that is anticipated to grow with CAGR of 64.66% during the forecast period, 2023-2027 to achieve market value of USD33153.30 million by 2027F. Increasing instances of cancer among the world population and thus increasing death rate due to cancer is driving the growth of the global CAR-T cell therapy market in the upcoming five years. Rapidly growing clinical trial activities, proliferative M & A activities, and lucrative IPOs are majorly responsible for the growth of the global CAR-T cell therapy market in the next five years. Consistent researches on cancer and its treatment along with the advancement in the therapeutics are further substantiating the growth of the global CAR-T cell therapy market in the future five years. Increasing demand for the effective cancer treatment for the growing number of people suffering from cancer along with the flourishing pharmaceutical industry producing products and therapies for the cancer are also responsible for the growth of the global CAR-T cell therapy market in the forecast years through 2027. Although side-effects of the CAR-T cells therapy and high cost of treatment making it unaffordable to the financially challenged population may restrain the growth of the market. Government schemes, tax incentives, along with insurance policies for the treatment and increasing number of NGOs working for providing in-expensive treatment to the patients lacking financial support may aid the growth of the global CAR-T cell therapy market in the forecast period.

The global CAR-T cell therapy market is segmented by product type, tumor type, indication, treatment type, targeted antigen, end user, regional distribution, and competition landscape. Based on treatment type, the market is further segmented into single treatment and combination treatment. Single treatment is anticipated to hold the largest revenue shares of the market and dominate the market segment in the upcoming five years on grounds of increasing cases of cancer among the population. Increasing awareness about the cancer diagnostics and early recognition of the tests are responsible for the patients opting for single treatment. Cancer in early stages can be treated with single treatments. The combination treatments are recent developments where multiple therapies are involved together to stop the cancer tumor development, to remove the lumps, and even alter the genetic information.

Gilead Sciences Inc, Novartis International AG, Bristol Myers Squibb Company, AbbVie Inc., Cellectis SA, Amgen Inc, Pfizer Inc, Merck & Co. Inc., Intellia Therapeutics Inc., Poseida Therapeutics Inc, Johnson & Johnson, Allogene Therapeutics Inc, Autolus Therapeutics PLC, Humanigen, Inc, Sangamo Therapeutics, Inc, and among others are among the major market players in the regional platform that lead the market growth of the global CAR-T cell therapy market.

Years considered for this report:

  • Historical Years: 2017-2020
  • Base Year: 2021
  • Estimated Year: 2022
  • Forecast Period: 2023-2027

Objective of the Study:

  • To analyze the market size of global CAR-T cell therapy market from 2017 to 2020.
  • To estimate and forecast the market size of global CAR-T cell therapy market from 2021 to 2022 and growth rate until 2027.
  • To classify and forecast global CAR-T cell therapy market based on product type, tumor type, indication, treatment type, targeted antigen, end user, regional distribution, and competition landscape.
  • To identify dominant region or segment in the global CAR-T cell therapy market.
  • To identify drivers and challenges for global CAR-T cell therapy market.
  • To examine competitive developments such as expansions, new product & service launches, mergers & acquisitions, etc., in global CAR-T cell therapy market.
  • To identify and analyze the profile of leading players operating in global CAR-T cell therapy market.
  • To identify key sustainable strategies adopted by market players in global CAR-T cell therapy market.

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of manufacturers & service providers across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the manufacturers & service providers which could not be identified due to the limitations of secondary research. TechSci Research analyzed the manufacturers & service providers, distribution channels and presence of all major players across the globe.

TechSci Research calculated the market size of global CAR-T cell therapy market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these products & services and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.

Key Target Audience:

  • Manufacturers & service providers, suppliers
  • Distributors and other stakeholders
  • Government bodies such as regulating authorities and policy makers
  • Organizations, forums and alliances related to CAR-T cell therapy
  • Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as manufacturers, service providers, suppliers, partners, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, global CAR-T cell therapy market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

CAR-T Cell Therapy, By Product Type:

  • Yescarta (Axicabtagene Ciloleucel)
  • Kymriah (Tisagenlecleucel)
  • Tecartus (Brexucabtagene Autoleucel)
  • Breyanzi (Lisocabtagene Maraleucel)
  • Abecma (Idecabtagene Vicleucel)
  • Others

CAR-T Cell Therapy Market, By Tumor Type:

  • Hematological Malignancies
  • Solid Tumors

CAR-T Cell Therapy Market, By Indication:

  • Diffused Large B-Cell Lymphoma (DLBCL)
  • Acute Lymphoblastic Leukemia (ALL)
  • Follicular Lymphoma (FL)
  • Mantle Cell Lymphoma (MCL)
  • Others

CAR-T Cell Therapy Market, By Treatment Type:

  • Single Treatment
  • Combination Treatment

CAR-T Cell Therapy Market, By Targeted Antigen

  • CD19
  • BCMA
  • Others

CAR-T Cell Therapy Market, By End User:

  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers
  • Others

CAR-T Cell Therapy Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • United Kingdom
    • Switzerland
    • Italy
    • Spain
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
  • South America
    • Columbia
    • Brazil
    • Argentina
  • Middle East & Africa
    • Israel
    • Saudi Arabia
    • South Africa
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global CAR-T cell therapy market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Impact of COVID-19 on Global CAR-T Cell Therapy Market

4. Executive Summary

5. Voice of Customers

  • 5.1. Brand Awareness
  • 5.2. Unmet Need and Challenges
  • 5.3. Factors Driving the CAR-T Cell Therapy Market

6. Global CAR-T Cell Therapy Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product Type (Yescarta (Axicabtagene Ciloleucel), Kymriah (Tisagenlecleucel), Tecartus (Brexucabtagene Autoleucel), Breyanzi (Lisocabtagene Maraleucel), Abecma (Idecabtagene Vicleucel), Others)
    • 6.2.2. By Tumor Type (Hematological Malignancies, Solid Tumors)
    • 6.2.3. By Indication (Diffused Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Others)
    • 6.2.4. By Treatment Type (Single Treatment, Combination Treatment)
    • 6.2.5. By Targeted Antigen (CD 19, BCMA (B-Cell Maturation Antigen), Others)
    • 6.2.6. By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)
    • 6.2.7. By Region
    • 6.2.8. By Company
  • 6.3. Product Market Map

7. North America CAR-T Cell Therapy Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product Type
    • 7.2.2. By Tumor Type
    • 7.2.3. By Indication
    • 7.2.4. By Treatment Type
    • 7.2.5. By Targeted Antigen
    • 7.2.6. By End User
    • 7.2.7. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States CAR-T Cell Therapy Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product Type
        • 7.3.1.2.2. By Tumor Type
        • 7.3.1.2.3. By Indication
        • 7.3.1.2.4. By Treatment Type
        • 7.3.1.2.5. By Targeted Antigen
        • 7.3.1.2.6. By End User
    • 7.3.2. Canada CAR-T Cell Therapy Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product Type
        • 7.3.2.2.2. By Tumor Type
        • 7.3.2.2.3. By Indication
        • 7.3.2.2.4. By Treatment Type
        • 7.3.2.2.5. By Targeted Antigen
        • 7.3.2.2.6. By End User
    • 7.3.3. Mexico CAR-T Cell Therapy Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product Type
        • 7.3.3.2.2. By Tumor Type
        • 7.3.3.2.3. By Indication
        • 7.3.3.2.4. By Treatment Type
        • 7.3.3.2.5. By Targeted Antigen
        • 7.3.3.2.6. By End User

8. Europe CAR-T Cell Therapy Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product Type
    • 8.2.2. By Tumor Type
    • 8.2.3. By Indication
    • 8.2.4. By Treatment Type
    • 8.2.5. By Targeted Antigen
    • 8.2.6. By End User
    • 8.2.7. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. Germany CAR-T Cell Therapy Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product Type
        • 8.3.1.2.2. By Tumor Type
        • 8.3.1.2.3. By Indication
        • 8.3.1.2.4. By Treatment Type
        • 8.3.1.2.5. By Targeted Antigen
        • 8.3.1.2.6. By End User
    • 8.3.2. France CAR-T Cell Therapy Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product Type
        • 8.3.2.2.2. By Tumor Type
        • 8.3.2.2.3. By Indication
        • 8.3.2.2.4. By Treatment Type
        • 8.3.2.2.5. By Targeted Antigen
        • 8.3.2.2.6. By End User
    • 8.3.3. Switzerland CAR-T Cell Therapy Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product Type
        • 8.3.3.2.2. By Tumor Type
        • 8.3.3.2.3. By Indication
        • 8.3.3.2.4. By Treatment Type
        • 8.3.3.2.5. By Targeted Antigen
        • 8.3.3.2.6. By End User
    • 8.3.4. United Kingdom CAR-T Cell Therapy Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product Type
        • 8.3.4.2.2. By Tumor Type
        • 8.3.4.2.3. By Indication
        • 8.3.4.2.4. By Treatment Type
        • 8.3.4.2.5. By Targeted Antigen
        • 8.3.4.2.6. By End User
    • 8.3.5. Italy CAR-T Cell Therapy Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product Type
        • 8.3.5.2.2. By Tumor Type
        • 8.3.5.2.3. By Indication
        • 8.3.5.2.4. By Treatment Type
        • 8.3.5.2.5. By Targeted Antigen
        • 8.3.5.2.6. By End User
    • 8.3.6. Spain CAR-T Cell Therapy Market Outlook
      • 8.3.6.1. Market Size & Forecast
        • 8.3.6.1.1. By Value
      • 8.3.6.2. Market Share & Forecast
        • 8.3.6.2.1. By Product Type
        • 8.3.6.2.2. By Tumor Type
        • 8.3.6.2.3. By Indication
        • 8.3.6.2.4. By Treatment Type
        • 8.3.6.2.5. By Targeted Antigen
        • 8.3.6.2.6. By End User

9. Asia-Pacific CAR-T Cell Therapy Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product Type
    • 9.2.2. By Tumor Type
    • 9.2.3. By Indication
    • 9.2.4. By Treatment Type
    • 9.2.5. By Targeted Antigen
    • 9.2.6. By End User
    • 9.2.7. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. China CAR-T Cell Therapy Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product Type
        • 9.3.1.2.2. By Tumor Type
        • 9.3.1.2.3. By Indication
        • 9.3.1.2.4. By Treatment Type
        • 9.3.1.2.5. By Targeted Antigen
        • 9.3.1.2.6. By End User
    • 9.3.2. Japan CAR-T Cell Therapy Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product Type
        • 9.3.2.2.2. By Tumor Type
        • 9.3.2.2.3. By Indication
        • 9.3.2.2.4. By Treatment Type
        • 9.3.2.2.5. By Targeted Antigen
        • 9.3.2.2.6. By End User
    • 9.3.3. India CAR-T Cell Therapy Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product Type
        • 9.3.3.2.2. By Tumor Type
        • 9.3.3.2.3. By Indication
        • 9.3.3.2.4. By Treatment Type
        • 9.3.3.2.5. By Targeted Antigen
        • 9.3.3.2.6. By End User
    • 9.3.4. Australia Global CAR-T Cell Therapy Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Type
        • 9.3.4.2.2. By Product Type
        • 9.3.4.2.3. By Technology
        • 9.3.4.2.4. By Duration
        • 9.3.4.2.5. By Application
        • 9.3.4.2.6. By End User
    • 9.3.5. South Korea Global CAR-T Cell Therapy Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Type
        • 9.3.5.2.2. By Product Type
        • 9.3.5.2.3. By Technology
        • 9.3.5.2.4. By Duration
        • 9.3.5.2.5. By Application
        • 9.3.5.2.6. By End User

10. South America CAR-T Cell Therapy Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product Type
    • 10.2.2. By Tumor Type
    • 10.2.3. By Indication
    • 10.2.4. By Treatment Type
    • 10.2.5. By Targeted Antigen
    • 10.2.6. By End User
    • 10.2.7. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil CAR-T Cell Therapy Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Product Type
        • 10.3.1.2.3. By Technology
        • 10.3.1.2.4. By Duration
        • 10.3.1.2.5. By Application
        • 10.3.1.2.6. By End User
    • 10.3.2. Argentina CAR-T Cell Therapy Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Product Type
        • 10.3.2.2.3. By Technology
        • 10.3.2.2.4. By Duration
        • 10.3.2.2.5. By Application
        • 10.3.2.2.6. By End User
    • 10.3.3. Colombia CAR-T Cell Therapy Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Product Type
        • 10.3.3.2.3. By Technology
        • 10.3.3.2.4. By Duration
        • 10.3.3.2.5. By Application
        • 10.3.3.2.6. By End User

11. Middle East & Africa CAR-T Cell Therapy Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Product Type
    • 11.2.2. By Tumor Type
    • 11.2.3. By Indication
    • 11.2.4. By Treatment Type
    • 11.2.5. By Targeted Antigen
    • 11.2.6. By End User
    • 11.2.7. By Country
  • 11.3. Middle East & Africa: Country Analysis
    • 11.3.1. Israel CAR-T Cell Therapy Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Type
        • 11.3.1.2.2. By Product Type
        • 11.3.1.2.3. By Technology
        • 11.3.1.2.4. By Duration
        • 11.3.1.2.5. By Application
        • 11.3.1.2.6. By End User
    • 11.3.2. Saudi Arabia CAR-T Cell Therapy Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Type
        • 11.3.2.2.2. By Product Type
        • 11.3.2.2.3. By Technology
        • 11.3.2.2.4. By Duration
        • 11.3.2.2.5. By Application
        • 11.3.2.2.6. By End User
    • 11.3.3. UAE Global CAR-T Cell Therapy Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Type
        • 11.3.3.2.2. By Product Type
        • 11.3.3.2.3. By Technology
        • 11.3.3.2.4. By Duration
        • 11.3.3.2.5. By Application
        • 11.3.3.2.6. By End User
    • 11.3.4. South Africa CAR-T Cell Therapy Market Outlook
      • 11.3.4.1. Market Size & Forecast
        • 11.3.4.1.1. By Value
      • 11.3.4.2. Market Share & Forecast
        • 11.3.4.2.1. By Type
        • 11.3.4.2.2. By Product Type
        • 11.3.4.2.3. By Technology
        • 11.3.4.2.4. By Duration
        • 11.3.4.2.5. By Application
        • 11.3.4.2.6. By End User

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

14. Competitive Landscape

  • 14.1. Competition Outlook
  • 14.2. Company Profiles
    • 14.2.1. Gilead Sciences, Inc
    • 14.2.2. Novartis International AG
    • 14.2.3. Bristol Myers Squibb Co.
    • 14.2.4. AbbVie Inc.
    • 14.2.5. Cellectis SA
    • 14.2.6. Amgen Inc
    • 14.2.7. Pfizer Inc.
    • 14.2.8. Merck & Co. Inc.
    • 14.2.9. Intellia Therapeutics Inc.
    • 14.2.10. Poseida Therapeutics Inc
    • 14.2.11. Johnson & Johnson
    • 14.2.12. Allogene Therapeutics Inc
    • 14.2.13. Autolus Therapeutics PLC
    • 14.2.14. Humanigen, Inc.
    • 14.2.15. Sangamo Therapeutics, Inc.

15. Strategic Recommendations